Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Background: Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis. Based on evidence from clinical trials, tildrakizumab is approved for the treatment of moderate-to-severe plaque psoriasis in patient...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
BioExcel Publishing Ltd,
2021-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|